Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy

Niels Fisker, Majken Westergaard, Henrik Frydenlund Hansen, Jens Bo Hansen

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

We have investigated the effects of different locked nucleic acid modified antisense mRNA antagonists against Survivin in a prostate cancer model. These mRNA antagonists were found to be potent inhibitors of Survivin expression at low nanomolar concentrations. Additionally there was a pronounced synergistic effect when combining the mRNA antagonists against Survivin with the chemotherapeutic Taxol. This effect was demonstrated at concentrations of antagonists far lower than any previously demonstrated, indicating the high potential of locked nucleic acid for therapeutic use. Further characterisations in vivo are ongoing.

Original languageEnglish
JournalNucleosides, Nucleotides and Nucleic Acids
Volume26
Issue number10-12
Pages (from-to)1427-1430
ISSN1525-7770
DOIs
Publication statusPublished - 2007
Externally publishedYes

Keywords

  • Antineoplastic Agents
  • Cell Line, Tumor
  • Humans
  • Inhibitor of Apoptosis Proteins
  • Male
  • Microtubule-Associated Proteins
  • Neoplasm Proteins
  • Oligonucleotides
  • Prostatic Neoplasms
  • RNA, Antisense
  • RNA, Messenger

Fingerprint

Dive into the research topics of 'Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy'. Together they form a unique fingerprint.

Cite this